AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption

被引:2
作者
Sun, Jiacheng [1 ,2 ]
Cai, Guoping [1 ,2 ]
Shen, Jinlong [1 ,2 ]
Cheng, Pu [1 ,2 ]
Zhang, Jiapeng [1 ,2 ]
Jiang, Dengteng [1 ,2 ]
Xu, Xianquan [1 ,2 ]
Lu, Fangying [1 ,2 ]
Chen, Lihua [1 ,2 ,3 ]
Chen, Haixiao [1 ,2 ,3 ]
机构
[1] Wenzhou Med Univ, Dept Orthopaed, Taizhou Hosp, Linhai, Zhejiang, Peoples R China
[2] Taizhou Hosp, Bone Dev & Metab Res Ctr, Linhai, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Dept Orthopaed, Taizhou Hosp, 150 Ximen Rd Linhai City, Taizhou, Zhejiang, Peoples R China
关键词
AS-605240; PI3K; osteoclast; Akt; osteoporosis; RANKL-MEDIATED OSTEOCLASTOGENESIS; IN-VITRO; T-CELLS; DIFFERENTIATION; PATHWAYS; BLOCKADE; RECEPTOR; 3-KINASE; NFAT;
D O I
10.2147/DDDT.S403231
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Osteoporosis is a metabolic bone disease. Osteoclasts are significantly involved in the pathogenesis of osteoporosis. AS-605240 (AS) is a small molecule PI3K-gamma inhibitor and is less toxic compared to pan-PI3K inhibitors. AS also exerts multiple biological effects including anti-inflammatory, anti-tumor, and myocardial remodeling promotion. However, the involvement of AS in the differentiation and functions of osteoclasts and the effect of AS in treating patients with osteoporosis is still unclear. Purpose: This study aimed to investigate if AS inhibits the differentiation of osteoclasts and resorption of the bones induced by M-CSF and RANKL. Next, we evaluated the therapeutic effects of AS on bone loss in ovariectomy (OVX)-induced osteoporosis mice models. Methods: We stimulated bone marrow-derived macrophages with an osteoclast differentiation medium containing different AS concentrations for 6 days or 5 mu M AS at different times. Next, we performed tartrate-resistant acid phosphatase (TRAP) staining, bone resorption assay, F-actin ring fluorescence, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting (WB). Next, MC3T3-E1s (pre-osteoblast cells) were differentiated to osteoblast by stimulating the cells with varying AS concentrations. Next, we performed alkaline phosphatase (ALP) staining, RT-qPCR, and WB on these cells. We established an OVX-induced osteoporosis mice model and treated the mice with 20mg/kg of AS. Finally, we extracted the femurs and performed micro-CT scanning, H&E, and TRAP staining. Results: AS inhibits the formation of osteoclasts and resorption of bone triggered by RANKL by inhibiting the PI3K/Akt signaling pathway. Furthermore, AS enhances the differentiation of osteoblasts and inhibits bone loss due to OVX in vivo. Conclusion: AS inhibits osteoclast production and enhances osteoblast differentiation in mice, thus providing a new therapeutic approach for treating patients with osteoporosis.
引用
收藏
页码:1275 / 1288
页数:14
相关论文
共 39 条
[1]   Clinical impact of bisphosphonates in root canal therapy [J].
AlRahabi, Mothanna K. ;
Ghabbani, Hani M. .
SAUDI MEDICAL JOURNAL, 2018, 39 (03) :232-238
[2]   The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes [J].
Azzi, Jamil ;
Moore, Robert F. ;
Elyaman, Wassim ;
Mounayar, Marwan ;
El Haddad, Najib ;
Yang, Sunmi ;
Jurewicz, Mollie ;
Takakura, Ayumi ;
Petrelli, Alessandra ;
Fiorina, Paolo ;
Ruckle, Thomas ;
Abdi, Reza .
DIABETES, 2012, 61 (06) :1509-1518
[3]   PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus [J].
Barber, DF ;
Bartolomé, A ;
Hernandez, C ;
Flores, JM ;
Redondo, C ;
Fernandez-Arias, C ;
Camps, M ;
Ruckle, T ;
Schwarz, MK ;
Rodríguez, S ;
Martinez-A, C ;
Balomenos, D ;
Rommel, C ;
Carrera, AC .
NATURE MEDICINE, 2005, 11 (09) :933-935
[4]   Advances in the Regulation of Osteoclasts and Osteoclast Functions [J].
Boyce, B. F. .
JOURNAL OF DENTAL RESEARCH, 2013, 92 (10) :860-867
[5]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[6]   Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis [J].
Camps, M ;
Rückle, T ;
Ji, H ;
Ardissone, V ;
Rintelen, F ;
Shaw, J ;
Ferrandi, C ;
Chabert, C ;
Gillieron, C ;
Françon, B ;
Martin, T ;
Gretener, D ;
Perrin, D ;
Leroy, D ;
Vitte, PA ;
Hirsch, E ;
Wymann, MP ;
Cirillo, R ;
Schwarz, MK ;
Rommel, C .
NATURE MEDICINE, 2005, 11 (09) :936-943
[7]   Biochemical markers of bone metabolism: An overview [J].
Christenson, RH .
CLINICAL BIOCHEMISTRY, 1997, 30 (08) :573-593
[8]   Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway [J].
Cui, Jin ;
Li, Xiaoqun ;
Wang, Sicheng ;
Su, Yiming ;
Chen, Xiao ;
Cao, Liehu ;
Zhi, Xin ;
Qiu, Zili ;
Wang, Yao ;
Jiang, Hao ;
Huang, Biaotong ;
Ji, Fang ;
Su, Jiacan .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (11) :6149-6161
[9]   The Role of Osteoclast Energy Metabolism in the Occurrence and Development of Osteoporosis [J].
Da, Wacili ;
Tao, Lin ;
Zhu, Yue .
FRONTIERS IN ENDOCRINOLOGY, 2021, 12
[10]   Glucocorticoids Enhanced Osteoclast Autophagy Through the PI3K/Akt/mTOR Signaling Pathway [J].
Fu, Lingjie ;
Wu, Wen ;
Sun, Xiaojiang ;
Zhang, Pu .
CALCIFIED TISSUE INTERNATIONAL, 2020, 107 (01) :60-71